公开(公告)号：EP1812026A2

公开(公告)日：2007-08-01

申请号：EP05818947.3

申请日：2005-11-10

申请人： Schering Aktiengesellschaft

发明人： BEIER, Rudolf ,  PÜHLER, Florian ,  WILLUDA, Hans Jörg

IPC分类号： A61K35/76 ,  C07K14/115

CPC分类号： C07K14/005 ,  A01K67/0271 ,  A01K2267/0331 ,  A61K8/34 ,  A61K8/35 ,  A61K8/37 ,  A61K8/4953 ,  A61K8/922 ,  A61K8/97 ,  A61K8/99 ,  A61K35/768 ,  A61K38/1709 ,  A61K38/2013 ,  A61K38/47 ,  A61Q19/08 ,  C07K2319/33 ,  C12N2760/18122 ,  C12N2760/18132 ,  C12N2760/18143 ,  A61K2300/00

摘要： The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.